title: Potential therapeutic uses of mecamylamine and its stereoisomers.
abstract: Mecamylamine (3-methylaminoisocamphane hydrochloride) is a nicotinic parasympathetic ganglionic blocker, originally utilized as a therapeutic agent to treat hypertension. Mecamylamine administration produces several deleterious side effects at therapeutically relevant doses. As such, mecamylamine's use as an antihypertensive agent was phased out, except in severe hypertension. Mecamylamine easily traverses the blood-brain barrier to reach the central nervous system (CNS), where it acts as a nicotinic acetylcholine receptor (nAChR) antagonist, inhibiting all known nAChR subtypes. Since nAChRs play a major role in numerous physiological and pathological processes, it is not surprising that mecamylamine has been evaluated for its potential therapeutic effects in a wide variety of CNS disorders, including addiction. Importantly, mecamylamine produces its therapeutic effects on the CNS at doses 3-fold lower than those used to treat hypertension, which diminishes the probability of peripheral side effects. This review focuses on the pharmacological properties of mecamylamine, the differential effects of its stereoisomers, S(+)- and R(-)-mecamylamine, and the potential for effectiveness in treating CNS disorders, including nicotine and alcohol addiction, mood disorders, cognitive impairment and attention deficit hyperactivity disorder.
authors.affiliation: Department of Pharmaceutical Sciences, College of Pharmacy, University of Kentucky, Lexington, KY 40536, USA. jnick2@uky.edu
authors.forename: Justin R
authors.initials: JR
authors.lastname: Nickell
authors.forename: Vladimir P
authors.initials: VP
authors.lastname: Grinevich
authors.forename: Kiran B
authors.initials: KB
authors.lastname: Siripurapu
authors.forename: Andrew M
authors.initials: AM
authors.lastname: Smith
authors.forename: Linda P
authors.initials: LP
authors.lastname: Dwoskin
mesh_terms: D000818:Animals; D004353:Drug Evaluation, Preclinical; D006801:Humans; D008464:Mecamylamine / Q000737:chemistry / Q000627:therapeutic use*; D018733:Nicotinic Antagonists / Q000737:chemistry / Q000627:therapeutic use*; D013237:Stereoisomerism
chemical_list: D018733:Nicotinic Antagonists; D008464:Mecamylamine